Kevin Okeefe, MD
Internal Medicine · Annapolis, MDNPI 1841398633
Payments from drug & device makers
What this record shows
4 manufacturers reported payments, led by Stryker at 54.7% of the total. Reporting peaked in 2019 at $110 and has fallen 83.2% since, to $18 in 2025. That places this record below the midpoint for internal medicine clinicians in MD, where the typical reported total is $161.
Across 6 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$82
- Philips North America LLC$28
- Almatica Pharma LLC$21
- Cook Medical LLC$18
What the payments were for
- Travel & lodging$8255%
- Food & beverage$6845%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 1 | $82 |
| Philips North America LLC | 2 | $28 |
| Almatica Pharma LLC | 1 | $21 |
| Cook Medical LLC | 2 | $18 |
How this compares
$149 in reported general payments places this provider in the 45th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 295 | $389,232 |
| MounjaroTirzepatide | 205 | $230,502 |
| EliquisApixaban | 126 | $192,529 |
| JardianceEmpagliflozin | 125 | $153,219 |
| XareltoRivaroxaban | 68 | $96,818 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $46,085 |
| FarxigaDapagliflozin Propanediol | 33 | $45,358 |
| WegovySemaglutide | 27 | $38,969 |
| LinzessLinaclotide | 36 | $31,603 |
| TrulicityDulaglutide | 20 | $31,221 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $29,500 |
| ProliaDenosumab | 12 | $21,637 |
| Dexlansoprazole DrDexlansoprazole | 56 | $20,243 |
| XifaxanRifaximin | 12 | $19,596 |
| Victoza 3-PakLiraglutide | 12 | $17,633 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Annapolis
- Brian HarveyAnnapolis$220K
- Aditya ChopraAnnapolis$85K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.